Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has provided an update.
Guangzhou Innogen Pharmaceutical Group has announced a change in its company secretarial team, with Jin Jin resigning as joint company secretary for personal development reasons, and the board emphasizing that there are no disagreements or issues related to her departure that would affect shareholders or the exchange. The company has appointed its legal director, Yang Dongyan, as the new joint company secretary alongside existing joint company secretary Sze Suet Ling, and has secured a waiver from strict compliance with certain Hong Kong Listing Rules to allow Yang’s appointment despite her not holding the usual formal qualifications, relying instead on her legal background, familiarity with the group’s operations, and support from Sze, who is fully qualified and will help ensure regulatory compliance and continuity in corporate governance.
The most recent analyst rating on (HK:2591) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H stock, see the HK:2591 Stock Forecast page.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in the People’s Republic of China, listed on the Hong Kong Stock Exchange. The group focuses on drug development and related healthcare operations through its subsidiaries, serving the broader medical and healthcare market in China and potentially international investors via its Hong Kong listing.
Average Trading Volume: 1,102,969
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.8B
For detailed information about 2591 stock, go to TipRanks’ Stock Analysis page.